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Soil-transmitted helminth infections in humans and livestock cause signiﬁcant debility, reduced pro-
ductivity and economic losses globally. There are a limited number of effective anthelmintic drugs
available for treating helminths infections, and their frequent use has led to the development of resis-
tance in many parasite species. There is an urgent need for novel therapeutic drugs for treating these
parasites. We have chosen the ACR-16 nicotinic acetylcholine receptor of Ascaris suum (Asu-ACR-16), as a
drug target and have developed three-dimensional models of this transmembrane protein receptor to
facilitate the search for new bioactive compounds. Using the human a7 nAChR chimeras and Torpedo
marmorata nAChR for homology modeling, we deﬁned orthosteric and allosteric binding sites on the
Asu-ACR-16 receptor for virtual screening. We identiﬁed four ligands that bind to sites on Asu-ACR-16
and tested their activity using electrophysiological recording from Asu-ACR-16 receptors expressed in
Xenopus oocytes. The four ligands were acetylcholine inhibitors (SB-277011-A, IC50, 3.12 ± 1.29 mM;
(þ)-butaclamol Cl, IC50, 9.85 ± 2.37 mM; fmoc-1, IC50, 10.00 ± 1.38 mM; fmoc-2, IC50, 16.67 ± 1.95 mM) that
behaved like negative allosteric modulators. Our work illustrates a structure-based in silico screening
method for seeking anthelmintic hits, which can then be tested electrophysiologically for further
characterization.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Soil-transmitted gastrointestinal nematodes, namely round-
worms, whipworms and hookworms, infect approximately two
billion people worldwide and pose a signiﬁcant health challenge to
humans and animals (de Silva et al., 2003; Bethony et al., 2006). The
infections with the soil-transmitted helminths can cause malnu-
trition, iron-deﬁciency anemia and impaired cognitive perfor-
mance (Crompton, 2000; Hotez et al., 2007). Currently, there are no
effective vaccines available (Hewitson and Maizels, 2014), and
sanitation is not adequate in many countries. The World Health
Organization (WHO) recommends four anthelmintics for treatment
and prophylaxis of soil-transmitted nematode infections:smembrane and intracellular
subunit; NAM, negative allo-
eptor; AChBP, acetylcholine-
011-1250, USA.
.
r Ltd on behalf of Australian Sociealbendazole, mebendazole, levamisole and pyrantel (Keiser and
Utzinger, 2008). The repeated use of a limited number of anthel-
mintic drugs has led to an increase in drug resistance in animals
and there are similar concerns for humans. It is therefore important
to identify novel therapeutic compounds that selectively target
receptors of parasitic nematodes so that we maintain effective
therapeutics.
The nicotinic acetylcholine receptors (nAChRs) are pentameric
ligand-gated ion channels that mediate synaptic transmission at
neuromuscular junctions of vertebrates and invertebrates
(Changeux and Edelstein, 1998). The neurotransmitter, acetylcho-
line, activates nAChRs by binding to orthosteric binding sites on the
extracellular domain of the receptor and triggers the opening of the
channel pore in the transmembrane domain. The opening of the
nicotinic receptors leads to an inﬂux of sodium and calcium
depending on the receptor subtypes, as well as an output of po-
tassium ions, followed by membrane depolarization and muscle
contraction.
Nicotinic anthelmintics are selective agonists of nematodety for Parasitology. This is an open access article under the CC BY license (http://
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(Martin and Robertson, 2010; Buxton et al., 2014). There are three
different pharmacological subtypes of nAChRs present onmuscle of
Ascaris suum. The anthelmintics, levamisole and pyrantel are se-
lective agonists of L-subtypes of nAChRs in A. suum (Martin et al.,
2012). Bephenium selectively activates B-subtypes of nAChRs.
Nicotine and oxantel selectively activate N-subtypes of nAChRs in
A. suum (Qian et al., 2006). The anthelmintic monepantel activates
nAChRs which are composed of DEG-3-like subunits (Haemonchus.
contortus MPTL-1, Caenorhabditis. elegans ACR-20 and H. contortus
ACR-23 subunits (Rufener et al., 2010; Buxton et al., 2014). We have
selected the N-subtype of nAChR that is composed of ACR-16 sub-
units (Ballivet et al., 1996; Polli et al., 2015) for a drug target,
because it is pharmacologically different to the other nicotinic re-
ceptor subtypes (Raymond et al., 2000), for further study. Asu-ACR-
16 transcript has been found in A. suum muscle and may be
involved in locomotion.
The ACR-16 nicotinic acetylcholine receptor of A. suum (Asu-
ACR-16) is a homomeric receptor made up of ﬁve identical a sub-
units. Homomeric nAChRs have ﬁve identical orthosteric binding
sites where agonists and competitive antagonists bind at the
interface of two adjacent subunits. The orthosteric site is in the
extracellular domain and is formed by the loops A, B & C of the
principal subunit and by the loops D, E & F on the complementary
subunit (Galzi et al., 1991; Arias, 2000). In addition, three allosteric
binding sites close to the orthosteric binding sites in the extracel-
lular domain have been observed in the a7 nAChR-AChBP chimera
(Spurny et al., 2015). In the transmembrane domain, an intra-
subunit allosteric binding site has been found in Rattus. norvegicus
a7 nAChR (Young et al., 2008), while an intersubunit allosteric
binding site has been found in C. elegans glutamate-gated chloride
channel (GluCl) (Hibbs and Gouaux, 2011). These well-studied
binding sites in nAChRs or other Cys-loop receptors provided our
framework for characterizing putative orthosteric and allosteric
sites in Asu-ACR-16.
Because of the lack of a crystal structure for Asu-ACR-16, we
used homology modeling to predict the protein structure, based on
the observations that proteins with similar sequences usually have
similar structures (Cavasotto and Phatak, 2009). In this study, we
used homology modeling to predict the three-dimensional struc-
ture of Asu-ACR-16, based on the observed experimental structures
of the human a7 nAChR chimeras and the Torpedo marmorata
nAChR as templates. Virtual screening was performed for the ACR-
16 orthosteric binding sites, using the predicted structure to iden-
tify the potential candidates of agonists and competitive antago-
nists. Allosteric binding sites were also used to examine the binding
properties of the virtual screening hits. Subsequently, we tested the
pharmacological proﬁles of virtual screening hits on Asu-ACR-16
receptors expressed in Xenopus laevis oocytes, using a two-
electrode voltage clamp to test the activity of the hits on the
receptors.
2. Materials and methods
2.1. Identiﬁcation of template structures
We selected the extracellular domain of Asu-ACR-16 (ECD-Asu-
ACR-16) because it forms a homologomer that allows homology
modeling. In addition, many of the agonists that activate Asu-ACR-
16, acetylcholine, nicotine, cytisine, epibatidine (Abongwa et al.,
2016), are also known to bind to the orthosteric binding sites of
extracellular domain of Lymnaea stagnalis AChBP or A. california
AChBP (Celie et al., 2004; Li et al., 2011; Rucktooa et al., 2012; Olsen
et al., 2014a). In addition to the orthosteric binding site, three
separate allosteric binding sites in the extracellular domain of a7nAChR are now recognized (Bertrand et al., 2008; Pan et al., 2012;
Spurny et al., 2015), increasing the possibility of identifying allo-
steric modulators.
The amino acid sequence of Asu-ACR-16 (Fig. 1) was obtained
from the UniProtKB/SwissProt database with the accession number
F1KYJ9 (Wang et al., 2011). Structural templates were identiﬁed by
using BLASTP on NCBI network service (Altschul et al., 1997) and
PSI-BLAST on the ProtMod server (Rychlewski et al., 2000) by
searching in the Protein Data Bank (Berman et al., 2000). Three
crystal structures of human a7 nAChR chimeras with different
coecrystal ligands in orthosteric binding site were used: epi-
batidine bound (PDB code: 3SQ6; Li et al., 2011), no ligand (PDB
code: 3SQ9; Li et al., 2011), and a-bungarotoxin bound (PDB code:
4HQP; Huang et al., 2013). These structures were selected as the
templates for three different bound-forms of the ECD-Asu-ACR-16.
The three models were: the agonist-bound form ECD-Asu-ACR-16;
the apo form ECD-Asu-ACR-16 and; the antagonist-bound form
ECD-Asu-ACR-16 (Fig. 2A).
We modeled the transmembrane and intracellular domains of
Asu-ACR-16 (TID-Asu-ACR-16, Fig. 2B) because of the presence of an
intrasubunit allosteric binding site that is found in a7 nAChR and an
intersubunit allosteric binding site that is demonstrated in a Cys-
loop receptor, GluCl crystal structure in complex with ivermectin
(Young et al., 2008; Bertrand et al., 2008; Hibbs and Gouaux, 2011).
Ivermectin is a known allosteric modulator of a7 nAChRs (Krause
et al., 1998). The T. marmorata nAChR (PDB code: 2BG9 chain A;
Unwin, 2005) is the only pentameric nAChR structure with the
transmembrane domains and partial intracellular domains deter-
mined. Therefore, the transmembrane and intracellular domains of
T. marmorata nAChR (TID-Tma-nAChR) were selected as the tem-
plate for our TID-Asu-ACR-16 model.
The sequence of the ECD-Asu-ACR-16 and the human a7 nAChR
chimera (SwissProt ID: P36544; Peng et al., 1994) were aligned
using CLUSTALW multiple alignment (Thompson et al., 1994). The
sequence of the TID-Asu-ACR-16 and TID-Tma-nAChR (SwissProt
ID: P02711; Devillers-Thiery et al., 1983, 1984) were aligned using
CLUSTALW.
2.2. Homology modeling of Asu-ACR-16
We used Modeller (Eswar et al., 2007) to build a three-
dimensional model of ECD-Asu-ACR-16 and used JACKAL (http://
wiki.c2b2.columbia.edu/honiglab_public/index.php/Software:
Jackal) to build the model of TID-Asu-ACR-16 for each of the ﬁve
subunits. These ﬁve subunits were then assembled to generate the
pentamer using COOT software (Emsley and Cowtan, 2004). The
model geometry was ﬁrst reﬁned manually, and then optimized by
PHENIX software (Adams et al., 2010). Each of the TID-Asu-ACR-16
subunits were then merged into the ECD-Asu-ACR-16 model by
using COOT to edit and alter the Ca coordinates of residues around
the outer membrane regions. The ﬁnal optimized pentameric
model was then visualized using the program PyMol (The PyMOL
Molecular Graphics System, Version 1.7.4, Schr€odinger, and LLC.,
Figs. 2C & S1).
2.3. Structure-based virtual screening
Smiles strings of ligands were downloaded from the lead-like
subset of commercially available compounds in the ZINC Data-
base (Irwin et al., 2012) and were converted initially to PDB formats
using the PHENIX-eLBOW program (Moriarty et al., 2009). The
ligand and receptor input ﬁles were then prepared in PDBQT format
for AutoDock Vina by using the AutoDock Tools package (Morris
et al., 2009). For initial screening, a docking area was deﬁned
visually around the orthosteric binding site of ECD-Asu-ACR-16
Fig. 1. (A) Sequence and numbering of the ECD-Asu-ACR-16 and its alignment with the template, human a7 nAChR chimera subunit. Completely conserved residues (red back-
ground) and partially conserved residues (yellow background) are indicated. Secondary structures are shown schematically above the sequences. a1 represents a helix. b1-7
represent b sheet. h1 represents a helix. The Cysteine loop and loops A - F are labeled by dark green bars. Residues in the orthosteric binding site are indicated by arrows (principal
subunit, pink; complementary subunit, orange). Residues in three allosteric binding pockets are highlighted by arrows (principal subunit of agonist sub-pocket, turquoise; com-
plementary subunit of agonist sub-pocket, green; principal subunit of vestibule pocket, dark green; complementary subunit of vestibule pocket, gold; principal subunit of top
pocket, purple). (B) Sequence and numbering of the TID-Asu-ACR-16 and its alignment with the template TID-Tma-AChR subunit A. Completely conserved residues (red back-
ground) and partially conserved residues (yellow background) are indicated. Four transmembrane a helixes (M1, M2, M3 and M4) are shown schematically above the sequences.
Residues in the allosteric binding pocket are indicated by arrows (principal subunit, pink; complementary subunit, orange). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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grid point spacing in AutoGrid. The conformations of ligands in the
binding sites of the receptor were searched with GALS (Genetic
Algorithm with Local Search; Morris et al., 1998). The binding free
energies between the ligands and receptor were calculated by the
combination of the knowledge-based and empirical scoring func-
tion in AutoDock Vina (Trott and Olson, 2010). The best nine
binding modes of the ligand based on the binding afﬁnities on the
three bound-forms of ECD-Asu-ACR-16 models were implemented
by AutoDock 20 runs for each ligand. Each docked ligand was then
ranked by its highest binding afﬁnity to the orthosteric binding siteof the apo, agonist-bound, or antagonist-bound model. From the
60,000 screened molecules, we selected the top 9 ligands (0.015%)
with the highest predicted afﬁnities that had appropriate binding
modes within the ligand-binding pockets for further study. We
rejected those compounds without a cationic nitrogen in their
structure and that were known to be: acutely toxic, or carcinogenic,
or respiratory depressants, caused dermatitis or conjunctivitis or to
be signiﬁcant environmental hazards as recorded on the compound
Safety Data Sheets available from Sigma Aldrich (http://www.
sigmaaldrich.com/safety-center.html).
The four virtual screen hits (Table 1) out of the top 9 selected
Fig. 2. (A) Ribbon diagram of the antagonist-bound model of ECD-Asu-ACR-16 viewed from the synaptic cleft, showing the location of the orthosteric binding site and agonist sub-
pocket. For clarity, only the front two subunits are highlighted (principal subunit, light pink; complementary subunit, yellow). The residues that contribute to the orthosteric binding
site (principal side, pink; complementary side, orange) and the agonist sub-pocket (principal side, turquoise; complementary side, green) are represented by sticks and highlighted
inside the red dotted circle. (B) Ribbon diagram of the antagonist-bound model of TID-Asu-ACR-16 viewed above the membrane, showing the location of two transmembrane
allosteric binding sites. For clarity, only the front two subunits are highlighted (principal subunit, light pink; complementary subunit, yellow). The residues that contribute to the
intersubunit site (principal side, pink; complementary side, orange) and intrasubunit site (principal side, purpleblue) are represented by sticks and highlighted inside the red dotted
circle. (C) Ribbon diagram of the antagonist-bound model of full-length Asu-ACR-16 viewed parallel to the membrane plane, showing the location of the orthosteric binding site and
the agonist sub-pocket in the extracellular domain, the intersubunit and intrasubunit binding sites in the transmembrane domain. For clarity, only the front two subunits are
highlighted (principal subunit, light pink; complementary subunit, yellow). The residues that contribute to the ligand binding sites are represented by sticks (orthosteric site: (þ),
pink; (), orange; agonist sub-pocket: (þ), turquoise; (), green; intersubunit transmembrane site: (þ), pink; (), orange; intrasubunit transmembrane site: purpleblue) and
highlighted inside the red dotted circle. (D) Detailed view of the orthosteric binding site and agonist sub-pocket in the antagonist-bound model of ECD-Asu-ACR-16. The principal
subunit is colored light pink, whereas the complementary subunit is colored yellow. The residues that contribute to the orthosteric binding site (principal side, pink; comple-
mentary side, orange) and the agonist sub-pocket (principal side, turquoise; complementary side, green) are represented by sticks and highlighted inside the red dotted circle.
Carbon is in either turquoise or green. Nitrogen is in blue. Oxygen is in red. (E) Detailed view of the transmembrane allosteric binding sites in the antagonist-bound model of TID-
Asu-ACR-16. The principal subunit is colored light pink, whereas the complementary subunit is colored yellow. The residues that contribute to intersubunit site (principal side, pink;
complementary side, orange) and intrasubunit site (principal side, purpleblue) are represented by sticks and highlighted inside the red dotted circle. Carbon is in either pink or
orange or purpleblue. Nitrogen is in blue. Oxygen is in red. Sulfur is in yellow. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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binding pockets: the agonist sub-pocket (Fig. S2C & S2D); thevestibule pocket (Fig. S2E & S2F); the top pocket (Fig. S2G & S2H);
the intersubunit and; the intrasubunit transmembrane sites (Fig. 2E
Table 1
Physicochemical properties and chemical structures of four virtual screen hits. The four hits are: fmoc-4-(naphthalen-2-yl)-piperidine-4-carboxylic acid (fmoc-2), SB-277011-
A hydrochloride hydrate (SB-277011-A), fmoc-4-(naphthalen-1-yl)-piperidine-4-carboxylic acid (fmoc-1), (þ)-butaclamol hydrochloride ((þ)-butaclamol Cl). The molecular
mass (Mol. Mass), number of hydrogen bondonors, number of hydrogen bond acceptors, number of rotatable bonds and partition coefﬁcient (xlogP) are listed for each hits.
ZINC ID 44122512 26574567 44122502 02008410
Hits fmoc-2 SB-277011-A fmoc-1 (þ)-butaclamol Cl
Structure
Mol. Mass 478 475 478 363
H-bondonors 0 1 0 2
H-bond acceptors 5 5 5 2
Rotatable bonds 5 5 5 1
XlogP 6.04 4.27 6.02 4.96
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steric binding pockets of Asu-ACR-16 by a grid box of
40 Å  40 Å  40 Å using 0.375 Å grid point spacing in AutoGrid.
The docking was performed by AutoDock Vina (Fig. 3).2.4. In vitro synthesis of cRNA and microinjection into Xenopus
laevis oocytes
We used TRIzol (Invitrogen™) to extract the total RNA samples
from a 1 cm muscle ﬂap and dissected the whole pharynx of
A. suum. The ﬁrst-strand of cDNAwas synthesizedwith oligo RACER
primer, Random Hexamer and superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) from total RNA in the muscle and
pharynx by reverse transcription polymerase chain reaction (RT-
PCR). Full-length Asu-acr-16 cDNA was ampliﬁed with the forward
primer TTGATGTAGTGGCGTCGTGT, ATCACGCATTACGGTTGATG and
the reverse primer GCATTGATGTTCCCTCACCT, ATTAGCGTCC-
CAAGTGGTTG (Boulin et al., 2011). The XhoI and ApaI restriction
enzymes were used to digest the ampliﬁed product, which was
then cloned into pTB207 expression vector (Boulin et al., 2008) and
linearized by NheI. We used the mMessage mMachine T7 kit
(Ambion) to in vitro transcribe the linearized cDNA to cRNA, which
was then precipitated with lithium chloride, re-suspended in
RNase-free water, aliquoted and stored at 80 C.
The ancillary proteinRIC-3 is required for the expression of ACR-16
in Xenopus oocytes (Halevi et al., 2003). A 50 nL cRNA mixture was
preparedwith 25ngAsu-acr-16 cRNA, 5 ngAsu-ric-3 cRNA (SwissProt
ID: F1L1D9; Wang et al., 2011) dissolved in RNAse-free water. The
nanoject II microinjector (Drummond Scientiﬁc, PA, USA)was used to
injected thecRNAmixture into theanimalpoleof thede-folliculatedX.
laevis oocyte (Ecocyte Bioscience, Austin, TX, USA).
The injected oocytes were separated into 96-well culture plates
and incubated in the incubation solution (pH 7.5), which is
composed of 100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2$2H2O, 1 mM
MgCl2$6H2O, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U/mL peni-
cillin, 100 mg/mL streptomycin and changed daily. The injected
oocytes were stored at 19 C for 4e8 days to allow the receptor to
be expressed.2.5. Two-electrode voltage-clamp oocyte recording
We used two-electrode voltage-clamp electrophysiology to re-
cord the inward current generated by the activated Asu-ACR-16 re-
ceptors expressed in X. laevis oocytes. 100 mM BAPTA-AM (ﬁnal
concentration) was added into the oocyte incubation solution 4 h
prior to recording, to prevent the current produced by the endoge-
nous calcium-activated chloride channels during recording. An
Axoclamp 2B ampliﬁer (Molecular Devices, CA, USA) was used for
recording and oocytes were held at 60 mV. A PC computer with
software Clampex 9.2 (Molecular Devices, CA, USA) was used to
acquire the recording data. The microelectrodes used to measure
current in oocytes were pulled on a Flaming/Brown horizontal
electrode puller (Model P-97, Sutter Instruments),ﬁlledwith 3MKCl
and had resistances of 20e30 MU. The microelectrode tips were
broken back carefully with Kimwipes (Wilmington, NC, USA) to
reduce the resistance to 2e5 MU. The recording solution was:
100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2$2H2O and 5 mM HEPES, pH
7.3 (Buxtonet al., 2014). Oocyteswereplaced intoa tinygroove of the
narrow oocyte recording chamber. The Digidata 1322A (Molecular
Devices, CA, USA) was used to control the switches that controlled
the perfusion of the chamber at a speed of 4e6 ml/min.
100 mMacetylcholine was applied initially for 10 s as a control to
check the viability of the oocytes and Asu-ACR-16 expression for all
the recordings. Recording solution was then used to wash out the
drug from the oocytes for 2e3 min before next application of drug
perfusion.
2.6. Drugs
Table 1 lists the compounds used, their chemical properties and
structures. Fmoc-4-(naphthalen-2-yl)-piperidine-4-carboxylic acid
(fmoc-2), SB-277011-A hydrochloride hydrate (SB-277011-A), fmoc-
4-(naphthalen-1-yl)-piperidine-4-carboxylic acid (fmoc-1) and
(þ)-butaclamol hydrochloride ((þ)-butaclamol Cl), acetylcholine
chloride (ach), methyllycaconitine citrate salt (mla) were purchased
from SigmaeAldrich (St Louis, MO, USA). Levamisole hydrochloride
(levamisole) was purchased from MP Biomedicals (Santa Ana, CA,
USA).With the exception of ach andmlawhich were dissolved in the
recording solution, the rest of chemicals were dissolved in dimethyl
sulfoxide (DMSO) tomake stock solutions. Stock solutions of 100mM
Fig. 3. Binding modes of four virtual screening hits in the orthosteric binding site, the agonist sub-pocket, the intersubunit and intrasubunit transmembrane allosteric binding
pockets of the antagonist-bound model of Asu-ACR-16: (A), (B), (C), (D) fomc-2; (E), (F), (G), (H) SB-277011-A; (I), (J), (K) fomc-1; (L), (M), (N), (O) (þ)-butaclamol Cl. Hits docked into
the binding pockets are represented by sticks (carbon in yellow; ring in white; nitrogen in blue; oxygen in red). (A), (E), (I) and (L) show the four hits bound in the orthosteric
binding site of the antagonist-bound model of ECD-Asu-ACR-16. The front two subunits are highlighted (principal subunit, light pink; complementary subunit, yellow). The residues
in the orthosteric binding site are labeled (principal side, pink; complementary side, orange) to show the location of the orthosteric binding site. (B), (F), (J) and (M) show the four
hits bound in the agonist sub-pocket of the antagonist-bound model of ECD-Asu-ACR-16. The front two subunits are highlighted. The residues in the agonist sub-pocket are labeled
(principal side, turquoise; complementary side, green) to show the location of the agonist sub-pocket. (C), (G) and (N) show the four hits bound in the intersubunit transmembrane
site of the antagonist-bound model of TID-Asu-ACR-16. The front two subunits are highlighted. The residues in the intersubunit transmembrane site are labeled (principal side,
pink; complementary side, orange) to show the location of the intersubunit transmembrane binding site. (D), (H), (K) and (O) show the four hits bound in the intrasubunit
transmembrane site of the antagonist-bound model of TID-Asu-ACR-16. The residues in the intrasubunit transmembrane site are labeled (purpleblue) to show the location of the
intersubunit transmembrane binding site. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
F. Zheng et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 60e73 65were prepared, except for SB-277011-A where a stock solution of
10 mM was prepared due to the solubility; stock solutions werefrozen until required. Working solutions were then prepared by
dilution on the day of the experiment.
Fig. 3. (continued)
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virtual screening
To characterize the four hits (Table 1) selected by our virtual
screening, each drug was applied for 10 s to the oocytes expressing
Asu-ACR-16 to test if the drugs were agonists. They were then
tested as antagonists against ach.
To characterize the antagonistic properties of the four hits, the
following protocol was used: a) 10 s of 100 mM ach alone; b) then
10 s of 100 mM ach þ hit and then; c) 10 s of 100 mM ach alone. This
test procedure was repeated with increasing concentrations of thefour hits (Fig. 4AeD), to determine the inhibitory doseeresponse
relationships and IC50 by ﬁtting Hill equations to the inhibitory
doseeresponse curves using GraphPad Prism 5.0 (Graphpad Soft-
ware Inc., CA, USA). As a further study of the antagonism, each of
the four hits was applied before and during 10 s test applications of
increasing concentrations of ach (Fig. S4).
2.8. Data analysis
The data from electrophysiological recordings were analyzed
using Clampﬁt 9.2 (Molecular Devices, CA, and USA) and GraphPad
Fig. 4. Effects of four virtual screening hits on Asu-ACR-16 mediated ach responses. Sample traces for: (A) fmoc-2, (B) SB-277011, (C) (þ)-butaclamol Cl, (D) fmoc-1 concentration-
inhibition relationships on Asu-ACR-16. Mla in (D), which stands for methyllycaconitine citrate salt, was used as an antagonist control of Asu-ACR-16. All four hits did not induce the
current response by themselves, while produced the concentration-depended inhibition of ach current response. (E) is the magniﬁed ﬁgure of part of (D) as an example to show the
four parameters needed to measure the inhibition percentage. Imax control was the peak current of the control 30 s application of 100 mM ach. Imax was the peak current of the 100 mM
ach that preceded the 10 s co-application of ach and antagonist. Iant was the minimal current during the co-application of 100 mM ach and antagonist. Iant control was the current at
the same time point from the beginning of the 30 s application as Iant during the control 30 s application of 100 mM ach.
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peak currents in response to applied drugs were measured, which
were later normalized to the control 100 mM ach response, and
expressed as mean ± S.E.M. The mean % inhibition of currents eli-
cited by 100 mM ach ± S.E.M. was used to determine the inhibition
percentage, which was quantiﬁed using the following equation:
Inhibitionð%Þ ¼
 
1 IantIant control
Imaxcontrol
 Imax
!
 100%
where Imax control was the peak current of the control 30 s appli-
cation of 100 mM ach, Imax was the peak current of the 100 mM achthat preceded the 10 s co-application of ach and antagonist. Iant was
the minimal current during the co-application of 100 mM ach and
antagonist. Iant control was the current at the same point from the
beginning of the 30 s application as Iant during the control 30 s
application of 100 mM ach (Fig. 4E). Concentration-response re-
lationships or concentration-inhibition (%) relationships were
analyzed by ﬁtting data points into the Hill equation, with at least
four replicates of each experiment set.
2.9. Drug treatment of C. elegans
The wild-type C. elegans strain N2 were obtained from the
Caenorhabditis Genetics Center (University of Minnesota, MN,
Table 2
Binding afﬁnities (kcal/mol) of the four hits and ach in the orthosteric binding sites of the three different boundmodels of ECD-Asu-ACR-16 and three allosteric binding sites of
the antagonist-bound model of full-length Asu-ACR-16.
Hits Binding afﬁnities (kcal/mol)
Apo Agonist-bound Antagonist-bound Transmembrane site
Orthosteric binding site Orthosteric binding site Orthosteric binding site Agonist sub-pocket Inter-subunit Intra-subunit
fmoc-2 10.4 13.0 10.2 8.5 11.4 10.8
SB-277011-A 9.8 12.3 9.2 9.5 10.8 9.7
fmoc-1 10.6 12.3 10.3 8.9 NA 11.0
(þ)-butaclamol Cl 9.5 11.8 8.2 9.2 10.8 9.0
ach 4.2 4.3 3.9 4.0 3.7 NA
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(NGM, 3 g/l NaCl, 17 g/l agar, 2.5 g/l peptone, 1 mM CaCl2, 5 mg/l
cholesterol, 1 mM MgSO4, 25 mM KPO4 buffer) agar plates, seeded
with Escherichia. coli OP50 lawn under standard conditions
(Brenner, 1974). Ten larvae at L4 stage with active thrashing
movement (deﬁned as “normal”) were transferred from NGM
plates into M9 buffer (3 g/l KH2PO4, 6 g/l Na2HPO4, 5 g/l NaCl, 1 mM
MgSO4) in 24-wall plates for each treatment. We counted the
number of worms with normal motility in M9 buffer with diluted
drugs from the stock solutions (1% DMSO) at 0, 5, 10, 15 and
20 min. Five replicates were applied for each treatment. Motility
between negative control (1% DMSO, ﬁnal concentration) and drug
treated worms were compared at each time point using student t-
test.
3. Results
3.1. Sequence alignment of Asu-ACR-16 and template homologue
proteins
The full-length protein sequence of Asu-ACR-16 (504 residues)
was retrieved from the SwissProt database, of which the ECD-Asu-
ACR-16 accounts for 234 residues. The ﬁrst 25 resides of Asu-ACR-
16 were excluded from alignment with the full length human
nAChR a7 chimera (204 residues) because of the shorter length of
the template protein sequence. The human a7 nAChR chimera
shows 37.6% sequence identity and 72.9% sequence similarity with
the ECD-Asu-ACR-16, based on the alignment generated by CLUS-
TALW (Fig.1A, job ID: 65782ad6ad6d). The TID-Tma-nAChR subunit
A shows 22.0% sequence identity and 45.4% sequence similarity
with TID-Asu-ACR-16, aligned by CLUSTALW (Fig. 1B, job ID:
644888f4f30e). The residues involved in the putative orthosteric
and the allosteric binding sites are highlighted in amino acids
sequence of Asu-ACR-16.
3.2. Models of the Asu-ACR-16 pentamer
The model of the antagonist-bound form of the ECD-Asu-ACR-
16 subunit starts from an N-terminal a helix followed by seven b
strands that comprise an immunoglobulin fold. Loop A (Val114 e
Ala122), loop B (Lys169 e Lys179), loop C (Phe213 e Pro220) from
the principal subunit, and loop D (Ala78 e Ala83), loop E (Ile143 e
Pro144), loop F (Gly185 e Met204) from the complementary sub-
unit are involved in forming the orthosteric binding site. A disul-
phide bond between Cys152 and Cys166 contributes to the
characteristic component of Cys-loop receptors. The C-terminal
continues into the transmembrane domain (Fig. S1A).
The transmembrane domains of the Asu-ACR-16 model are
made of four a-helices (M1, M2, M3 and M4). M1 links to the b7
sheet of the extracellular domain and extends down into the
membrane and is followed by the M2 and the M3 helixes as the
membrane-spanning portions. The MA cytoplasmic loop (helix)connects between M3 and M4. The region between M3 and MA is
not modeled due to the poorly deﬁned intracellular domain of the
template structure. The C-terminal follows the M4 helix and faces
toward the extracellular surface (Fig. S1B).
The pentameric model of Asu-ACR-16 has a ﬁve-fold symmetric
around the channel pore. The average pairwise Root Mean Square
Deviation (RMSD) ﬁt of the Ca coordinates of the antagonist-bound
ECD-Asu-ACR-16 pentameric model and human a7 nAChR chimera
pentamer (PDB code: 4HQP) was 0.9 Å, which indicates a strong
structural conservation between the model and the template
structures (Fig. S1C). The Ca-RMSD between the TID-Asu-ACR-16
pentamer and the TID-Tma-AChR pentamer was 1.5 Å, which
shows the TID ﬁt is still good but not as good as the ECD ﬁt. The
membrane-spanning domains are arranged symmetrically. The M2
helix lines the channel pore, while M1, M3 and M4 do not
contribute to the channel pore and are arranged peripherally
(Fig. S1D).
Since no binding site data of Asu-ACR-16 is available to date, we
used the published orthosteric binding site and allosteric binding
sites in nAChRs or other Cys-loop receptors to predict the putative
binding sites in Asu-ACR-16 (Galzi et al., 1991; Arias, 2000; Young
et al., 2008; Hibbs and Gouaux, 2011; Spurny et al., 2015). The
orthosteric binding site is at the interface between the principal site
and the complementary site in two adjacent subunits of the ECD-
Asu-ACR-16 pentamer (Fig. 2 S2A & S2B). The principal subunit
(þ) has vicinal cysteines (Cys216, Cys217) that contributes to the
loop C of the binding site. The complementary subunit () does not
use vicinal cysteines as part of the binding pocket and the residues
are more variable when nAChRs are compared. The agonist sub-
pocket, which we argue is a less signiﬁcant allosteric binding site
in ECD-Asu-ACR-16, is located right below the orthosteric binding
site in the extracellular domain (Fig. 2 S2C & S2D). The vestibule
pocket (Fig. S2E & S2F) and the top pocket (Fig. S2G & S2H) were
not high afﬁnity binding sites for the ligands and are not discussed
further in this manuscript. The intersubunit allosteric binding sites
in TID-Asu-ACR-16 are at the interface region between M2(þ),
M3(þ), M1() and M2() (Fig. 2 S2I & S2J). The intrasubunit allo-
steric binding sites are at the center of the four transmembrane
helixes (M1, M2, M3 and M4) in each of the ﬁve subunits.
3.3. Binding properties of virtual screening hits
We carried out virtual screening of the ZINC ligand-database by
using the three different bound forms of the ECD-Asu-ACR-16
models. Four molecules were selected as hits based on their high
binding afﬁnities and appropriate binding modes within the
ligand-binding sites. The 9-ﬂuorenylmethoxycarbonyl group
(FMOC) was observed in twelve out of top forty hits ranked by
binding afﬁnities and exists in the two out of four hits, which
suggests that FMOC could be necessary for the ligand recognition
by the receptor. The FMOC group has a low predicted bioavailability
due to the biphenyl scaffold, which limits aqueous solubility and
Fig. 5. (A) Effects of four virtual screening hits on Asu-ACR-16 mediated ach responses. Fmoc-2, fmoc-1, (þ)-butaclamol Cl and SB-277011-A concentration-inhibition curves for
Asu-ACR-16. Results were expressed as mean % inhibition of currents elicited by 100 mM ach ± S.E.M. (B) Bar chart representing the IC50 (mean ± S.E.M, mM) of each plots in (A). The
rank order series of inhibition based on IC50 for four hits is: SB-277011-A (3.12 ± 1.29 mM, n ¼ 4) < (þ)-butaclamol Cl (9.85 ± 2.37 mM, n ¼ 4) z fmoc-1 (10.00 ± 1.38 mM,
n ¼ 4) < fmoc-2 (16.67 ± 1.95 mM, n ¼ 4). * represents p < 0.05 (unpaired t-test). (C) Ach concentration-response plots for Asu-ACR-16 in the absence of hits as a control (ach) and in
the continual presence of four hits identiﬁed in (A). Ach concentration-response curves for Asu-ACR-16 in the presence of 3 mM of four hits: fmoc-1, fmoc-2, SB-27011-A and
(þ)-butaclamol Cl. (D) Bar chart (mean ± S.E.M, %) representing the reduced maximum current response of ach concentration-response curves in (C). The series of reduced
maximum response of each hits compared to that of ach by unpaired t-test is: 10 mM SB-27011-A (5.51 ± 1.38%, n ¼ 4), 3 mM (þ)-butaclamol Cl (17.22 ± 1.94%, n ¼ 4), 3 mM SB-27011-
A (23.25 ± 1.80%, n ¼ 5), 3 mM fmoc-2 (49.92 ± 3.27%, n ¼ 4), 3 mM fmoc-1 (61.25 ± 3.08%, n ¼ 4) and ach (97.45 ± 1.19%, n ¼ 4). * represents p < 0.05, ** represents p < 0.01, ***
represents p < 0.001. All four hits signiﬁcantly inhibited the maximum current response induced by ach. (E) Bar chart (mean ± S.E.M, mM) displaying the EC50 of ach concentration-
response curves in (C). The series of variable EC50 of each hits compared to that of ach by unpaired t-test is: 10 mM SB-27011-A (29.40 ± 2.27 mM, n ¼ 4), 3 mM fmoc-1
(8.62 ± 1.04 mM, n ¼ 4), 3 mM fmoc-2 (8.01 ± 0.18 mM, n ¼ 4), 3 mM SB-27011-A (7.17 ± 0.33 mM, n ¼ 5), ach (5.92 ± 0.29 mM, n ¼ 4) and 3 mM (þ)-butaclamol Cl
(3.94 ± 0.66 mM, n ¼ 4). The EC50 of all four hits obviously shift away from the control when applied.
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physicochemical characteristics of four hits. They have relatively
high molecular weights and are more hydrophobic compared to
known Asu-ACR-16 agonists. However, they do follow the Lipinski's
rule of ﬁve, which suggests that these molecules may be orally
actively (Lipinski et al., 2001; Lipinski, 2004).The atomic structure predicts the partition-coefﬁcients (XlogP)
of the four hits to be between 4.27 and 6.04 (Table 1). The XlogPs
suggest that the four hits are 10,000e1,000,000 times more
concentrated in the lipophilic phase of the lipid bilayer than the
aqueous phase of the extracellular domain (Cheng et al., 2007). The
four hydrophobic hits are, therefore, more likely to bind into the
Table 3
Pharmacological proﬁles of the inhibitory effects of four hits on Asu-ACR-16 medi-
ated ach responses. Results (mean ± S.E.M.) were expressed as IC50 (mM), Hill slope
(nH), maximum inhibition (%) and the number of repeats (N) of each experiment.
Hits IC50 (mM) nH Inhibitionmax (%) N
fmoc-2 16.67 ± 1.95 1.22 ± 0.17 80.34 ± 10.32 4
SB-277011-A 3.12 ± 1.29 0.99 ± 0.11 96.07 ± 10.66 4
fmoc-1 10.00 ± 1.38 1.97 ± 0.37 82.49 ± 4.74 4
(þ)-butaclamol Cl 9.85 ± 2.37 1.34 ± 0.29 79.53 ± 12.41 4
Table 4
Pharmacological proﬁles of EC50 shifts and maximum current reductions of Asu-
ACR-16 mediated ach responses in the presence and absence of four hits. Results
(mean ± S.E.M.) were expressed as EC50 (mM), Hill slope (nH) and maximum
response (%) and the number of repeats (N) of each experiment.
Hits EC50 (mM) nH Imax (%) N
control 5.92 ± 0.29 3.05 ± 0.07 97.45 ± 1.19 4
3 mM fmoc-2 8.01 ± 0.18 2.54 ± 0.18 49.92 ± 3.27 5
1 mM SB-277011-A 9.85 ± 4.80 2.60 ± 0.71 75.96 ± 4.40 4
3 mM SB-277011-A 7.17 ± 0.33 3.37 ± 0.28 23.25 ± 1.80 5
10 mM SB-277011-A 29.40 ± 2.27 7.43 ± 3.30 5.51 ± 1.38 4
3 mM fmoc-1 8.62 ± 1.04 1.76 ± 0.21 61.25 ± 3.08 4
1 mM (þ)-butaclamol Cl 4.54 ± 0.92 9.64 ± 4.14 30.34 ± 4.03 4
3 mM (þ)-butaclamol Cl 3.94 ± 0.66 12.75 ± 3.63 17.22 ± 1.94 4
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extracellular ligand binding sites. The four hits which bind in the
transmembrane allosteric binding pockets are therefore predicted
to be allosteric modulators of the Asu-ACR-16 receptor that alter
the activity of the agonists or competitive antagonists that bind to
orthosteric binding site. SB-277011-A is known to be a potent and
selective dopamine D3 receptor antagonist with high oral avail-
ability (Stemp et al., 2000). (þ)-butaclamol Cl is a non-selective
dopamine receptor antagonist and a potent antipsychotic agent
(Chrzanowski et al., 1985). No paper reporting on the activities of
fmoc-2 and fmoc-1 has been published to date.
The four hits (Table 1) were tested for docking into the orthos-
teric binding sites of the three forms of ECD-Asu-ACR-16 models
and the ﬁve allosteric binding pockets in the antagonist-bound
form of full-length Asu-ACR-16 models. All four hits bound to the
orthosteric binding sites of three ECD-Asu-ACR-16 models, but only
bound to the three allosteric binding sites out of ﬁve: the inter-
subunit and intrasubunit transmembrane pockets and the agonist
sub-pocket (Fig. 3) with high binding afﬁnities.
In the intersubunit transmembrane site of TID-Asu-ACR-16
model, M243 (M1, ()), L247 (M1, ()) make hydrophobic in-
teractions with naphthalene of fmoc-2. T312 (M3, (þ)), S284 (M2,
(þ)) form hydrogen bonds with carboxylic acids of fmoc-2. F279
(M2, ()), I282 (M2, ()) and make hydrophobic contacts with
ﬂuorene of fmoc-2. F279 (M2, ()), P244 (M1, ()) make hydro-
phobic interactions with tetrahydroisoquinoline of SB-277011-A.
N240 (M1, ()) forms a hydrogen bond with carboxamide of SB-
277011-A. P288 (M2, (þ)) has hydrophobic interactions with
quinoline of SB-277011-A. L247 (M1, ()), F279 (M2, ()) and
makes hydrophobic contacts with dibenzocycloheptene of
(þ)-butaclamol Cl.
Ach, the natural agonist of Asu-ACR-16 was docked into the
ligand binding sites of three forms of Asu-ACR-16 models for
comparison. As expected, ach bound to the orthosteric binding site
of the agonist-bound Asu-ACR-16 with an afﬁnity (4.3 kcal/mol),
which was higher than the afﬁnities at the other binding sites. The
binding pose of ach docked in the orthosteric binding site of the
agonist-bound Asu-ACR-16 model was in agreement with the
binding pose of ach in the L. stagnalis AChBP cocrystal structure(PDB code: 3WIP; Olsen et al., 2014b). The quaternary ammonium
of ach faces the basal side of the binding cavity and make cation-p
interaction with ﬁve aromatic residues from the Asu-ACR-16 ((þ):
Y89, W143, Y185, Y192; (): W53), while the carbonyl oxygen of
ach faces toward the apical side of the binding cavity. The binding
afﬁnities of the selected four compounds were higher
than 8.0 kcal/mol in the three different bound forms of Asu-ACR-
16, while the binding afﬁnities of ach were lower than 4.5 kcal/
mol in three states of Asu-ACR-16 (Table 2).
3.4. Pharmacological properties of virtual screening hits
We tested the effects of the putative allosteric modulators on
Asu-ACR-16 receptors expressed in Xenopus oocyte using two-
electrode voltage clamp to observe the currents that ﬂow through
Asu-ACR-16 receptors. Representative traces showing the inhibi-
tory doseeresponse relationships are shown in Fig. 4. Their IC50
(Fig. 5A and B) and maximum inhibition (Fig. S3) were determined
as described in the methods (Table 3). The most potent antagonist
among themwas SB-277011-A, which had an IC50 of 3.12 ± 1.29 mM
and maximum inhibition effect of 96.07 ± 10.66% (n ¼ 4).
The ach concentration-response plots in the presence of 3 mM of
each putative allosteric modulator (Fig. S4 & Fig. 5C), show the
reduced maximum current responses with little shift in EC50 of ach
(Fig. 5Dand E & Table 4), and that the hits were non-competitive
antagonists and negative allosteric modulators.
At 10 mM, SB-277011-A, showed evidence of a mixed competi-
tive and non-competitive antagonism (Fig. S5), characterized by a
reduced maximum current response and a right-shift in the EC50 of
ach (Fig. 5D and E). Thus, 10 mMSB-277011-A appears to act at more
than one binding site which may include the orthosteric binding
sites and additional allosteric binding sites.
3.5. SB-277011-A reversibly inhibits locomotion in C. elegans
We tested the effects of each allosteric modulator on the loco-
motion of C. elegans L4 larvae. The number of normal worms with
thrashing-like movement dropped by 60% in 5 min after exposed to
30 mM SB-277011-A (p < 0.01, n ¼ 5, t-test). Paralysis-like move-
ment was observed in the rest of the worms. Interestingly, the
number of worms with motility that appeared normal recovered to
50% (p < 0.05, n¼ 5, t-test) in 10min, 85% in 15min (p > 0.05, n¼ 5,
t-test) and returned to near negative control values after 20 min
(Fig. S6). The recovery may relate to the desensitization properties
of the ACR-16 receptor. The reversible inhibition of motility in
worms was also observed in 100 mM (þ)-butaclamol Cl, but no
signiﬁcant difference between the number of normal treated
worms and negative control was observed at any time point. No
visual effects of 100 mM fmoc-2 or 100 mM fmoc-1 were found on
the locomotion of worms.
4. Discussion
4.1. Asu-ACR-16 models
We have built up three-dimensional models of full-length
structures of Asu-ACR-16 at the atomic level for the ﬁrst time. We
used homology modeling based on X-ray crystal structures of hu-
man a7 nAChR chimeras and the electron microscopic structure of
the T. marmorata nAChR as templates for different domains. The
quality of our homology models are dependent on the sequence
identity of the templates (human a7 nAChR chimeras and
T. marmorata nAChR) and the target sequence (Asu-ACR-16) and the
resolutions of template structures (Hillisch et al., 2004; Cavasotto
and Phatak, 2009). Our three ECD-Asu-ACR-16 models are likely
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identities (37.6% identity and 72.9% similarity) with high resolution
(<4 Å) templates. More errors might be expected in the TID-Asu-
ACR-16 model, because of the missing loop between M3 and MA
in the template structure which reduces sequence identity with the
target protein. The missing loop does not include an allosteric
binding site, sowe can assume that the TID-Tma-nAChR structure is
similar to the TID-Asu-ACR-16 structure (Bertrand et al., 2008). The
overall secondary structures of our models are also consistent with
published nAChRs structures (Finer-Moore and Stroud, 1984;
Miyazawa et al., 2003; Unwin, 2005).
We developed the apo, the agonist-bound and the antagonist-
bound models of the ECD-Asu-ACR-16 on the assumption that
these three states of the Asu-ACR-16 receptor most closely repre-
sent the receptor conformations in the presence and absence of
agonists or antagonists. To produce a realistic dynamic model
would require more extensive work (Cavasotto and Orry, 2007;
Spyrakis et al., 2011) and is beyond the scope of this study.
4.2. Virtual screening
Our structure-based virtual screening approach identiﬁed four
novel and potent negative allosteric modulators of Asu-ACR-16,
which were validated by our electrophysiological studies. The pu-
tative ligands were initially selected based on the virtual screening
using the orthosteric binding site of the receptor. It was possible
that these ligands could have been agonists or competitive antag-
onists that bind within the orthosteric binding site. In contrast, the
pharmacological characterization of the four virtual screening hits
shows that they behave as negative allosteric modulators and bind
to allosteric sites. This outcome may be due to the hydrophobic
properties of the four compounds that impedes their interactions
with the orthosteric site in the extracellular domain of the receptor.
The high lipid solubility of these compounds increases their con-
centration in the membrane lipid phase, in the region of the
transmembrane allosteric sites.
The binding afﬁnities calculated in the scoring function of
AutoDock Vina software usually increase with the number of non-
hydrogen atoms, which may be due to the neglect of desolvation in
the scoring function (Shoichet et al., 1999; Kuntz et al., 1999; Park
et al., 2006). This leads to a bias of virtual screening methods to-
wards big molecules which are more hydrophobic, concentrated in
the lipid bilayer, and less likely to interact with the binding sites in
the extracellular domains (Hopkins et al., 2004). It is also pointed
out that the simpliﬁed force ﬁelds used to estimate the binding free
energies are unable to evaluate the conformational entropies and
other contributions to the free energies (Cosconati et al., 2010).
Thus, the success rate of identifying bioactive hits (44%) would be
enhanced if we are able to include these additional parameters into
a scoring function for virtual screening. Another approach, which
we did not follow here, to enhance the success rate of identifying
bio-active hits, is to use the known agonists or antagonists as
scaffolds. This would facilitate the identiﬁcation of low molecular-
weight and more hydrophilic agonists or antagonists, and allow
further study of the quantitative structure-activity relationships
(Sun, 2008).
4.3. Four negative allosteric modulators of Asu-ACR-16
We evaluated the potency of inhibition for the four negative
allosteric modulators in our electrophysiology studies on Xenopus
oocytes: SB-277011-A (IC50 3.12 ± 1.29 mM) < (þ)-butaclamol Cl
(IC50 9.85 ± 2.37 mM) z fmoc-1 (IC50 10.00 ± 1.38 mM) < fmoc-2
(IC50 16.67 ± 1.95 mM). This rank of inhibition agrees with the level
of effects of the four modulators in the motility of C. elegans. Themost potent modulator SB-277011-A was shown to decrease the
motility of C. elegans larvae for a duration of about 10 min, yet less
effective on adult C. elegans. Desensitization of the ACR-16 or other
nAChRs in C. elegans body muscle may be a reason for the reduced
effects of SB-277011-A on worms (Hernando et al., 2012). Treating
the acr-16-null mutant of C. elegans with SB-277011-A can help us
to investigate the mode of action of SB-277011-A on C. elegans as
genetic models to understand SB-277011-A action on the parasitic
nematode A. suum (Ward, 2015).4.4. Allosteric binding sites may offer a better opportunity for drugs
that can discriminate between the parasite Asu-ACR-16 and
mammalian host a7 nAChR
Asu-ACR-16 shows 42.5% sequence identity and 71.2% sequence
similarity with the human a7 nAChR (SwissProt ID: P36544) based
on the alignment generated by CLUSTALW (Fig. S7, CLUSTALW job
ID: cfed4f821eaf). The residues constituting the orthosteric binding
site (pink and orange arrows in Fig. S7) are highly conserved be-
tween Asu-ACR-16 and human a7 nAChR, which shows 66.7%
identity and 100% similarity (Fig. S8). In contrast, the residues of the
four allosteric binding sites have much greater differences (vari-
ance) between the nematode parasite and the equivalent sites on
the a7 receptor (identities: 62.5%, 45.5%, 66.7%, 62.5% and 40.0%
and; similarities: 87.5%, 81.8%, 83.3, 93.8% and 100%). The sequence
divergence in the allosteric binding sites between Asu-ACR-16 and
host human a7 nAChR indicates that drugs targeted at these sites
may be more selective than drugs targeted at orthosteric binding
sites. Virtual screening speciﬁcally targeting the allosteric binding
sites is predicted to offer a better opportunity for development of
drugs with much greater receptor subtype selectivity (Nussinov
and Tsai, 2013; Iturriaga-Vasquez et al., 2015).4.5. Conclusion
Wehave developed a structure-based in silico screening approach
to search for the bioactive hits that target at a parasitic nematode
receptor. This approach allowed us to identify four negative allosteric
modulators that were validated using our electrophysiological
studies. These four compoundsmay be useful leads for anthelminthic
drug discovery.We point out however, thatwe have not yetmade the
structural models for the host human a7 nAChR or other receptors,
which would help to distinguish compounds that are active only on
the nematode receptors, thereby reducing potential toxicity. It would
alsobedesirable to performvirtual screening for toxicity ona rangeof
host receptors, some structures of which have already been deter-
mined and others need to be modeled.Statement of conﬂict of interest
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